Q1 FY27 results: consolidated revenue up about 50% YoY, standalone posts loss
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.2 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 unaudited results. Consolidated revenue grew about 50% YoY to Rs 44,685 lakhs, but net profit fell to Rs 198.67 lakhs from Rs 2,659 lakhs due to Rs 96 lakhs exceptional items. Standalone posted Rs 51 lakh loss on Rs 8 lakh revenue. Auditor flagged going concern uncertainty at step-down subsidiary Genu Path Labs whose net worth is fully eroded. Also re-appointed Independent Director for 5 years. Composite restructuring scheme is pending approvals.
Sharp YoY profit drop and going concern flag at subsidiary may pressure the stock, though strong revenue growth offers some support.